Apellis price target lowered to $38 from $39 at Mizuho

Mizuho lowered the firm’s price target on Apellis (APLS) to $38 from $39 and keeps a Neutral rating on the shares. The firm recently conducted a survey of U.S. retinal specialists for their views on Syfovre and competitor product Izervay. The survey results indicate overall continued growth for the complement inhibitor class, an increase in prescribing for both Syfovre and Izervay; Syfovre remaining the market leader, and also having an advantage in terms of new patient starts, the analyst tells investors in a research note.